{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:10:11Z","timestamp":1777857011220,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:p>Myasthenia gravis is an autoimmune neuromuscular disease with a multifactorial etiology. A major part of the genetic susceptibility belongs to the HLA encoding genes. In this study, we investigated the role of HLA class II polymorphism in disease severity, and treatment response. In our 146 patients, 15 DRB1, 7 DQA1, and 9 DQB1 alleles, and 19 haplotypes were found. Adjusted p-values did not show any significant associations between these loci, disease severity and treatment outcome. Further studies in different populations with a larger number of patients are needed to determine the exact contribution of HLA class II alleles to MG prognosis.<\/jats:p>","DOI":"10.3233\/jnd-210700","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T13:45:45Z","timestamp":1622209545000},"page":"827-829","source":"Crossref","is-referenced-by-count":5,"title":["Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia Gravis"],"prefix":"10.1177","volume":"8","author":[{"given":"Farnaz","family":"Sinaei","sequence":"first","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Fatehi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Oveis Gharan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Ehsan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koorosh","family":"Kamali","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliakbar","family":"Amirzargar","sequence":"additional","affiliation":[{"name":"Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Rheumatology Research center (RRC), Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaleh","family":"Vaghefifar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahriar","family":"Nafissi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JND-210700_ref2","doi-asserted-by":"crossref","unstructured":"Li H-F , Hong Y , Xie Y , Hao H-J , Sun R-C . Precision medicine in myasthenia graves: Begin from the data precision. Annals of Translational Medicine. 2016;4(6).","DOI":"10.21037\/atm.2016.02.16"},{"issue":"4","key":"10.3233\/JND-210700_ref3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/imm.12869","article-title":"The immunogenetics of neurological disease","volume":"153","author":"Misra","year":"2018","journal-title":"Immunology"},{"issue":"1-2","key":"10.3233\/JND-210700_ref4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2015.11.021","article-title":"Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population","volume":"359","author":"Ehsan","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.3233\/JND-210700_ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JND-210700_ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","article-title":"Pharmacogenomic Biomarkers for Improved Drug Therapy\u2014Recent Progress and Future Developments","volume":"20","author":"Lauschke","year":"2017","journal-title":"AAPS Journal"},{"issue":"4","key":"10.3233\/JND-210700_ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.57.4.209","article-title":"HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments","volume":"57","author":"O\u2019Dell","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.3233\/JND-210700_ref8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1590\/0004-282x20180103","article-title":"Multiple sclerosis: Disease modifying therapy and the human leukocyte antigen","volume":"76","author":"Werneck","year":"2018","journal-title":"Arquivos de Neuro-psiquiatria"},{"issue":"1","key":"10.3233\/JND-210700_ref9","first-page":"1","article-title":"HLA-Genotype in multiple Sclerosis: The role in disease onset, clinical Course, cognitive status and response to Treatment: A clear step towards personalized therapeutics","volume":"2","author":"Stamatelos","year":"2017","journal-title":"Immunogenet Open Access"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:45Z","timestamp":1777506585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210700"}},"subtitle":[],"editor":[{"given":"Virginia","family":"Arechavala-Gomeza","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":8,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210700","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}